It is unclear whether these data simply reflect a lower availability of effective therapies for ERα- BC when compared to ERα+ BC, or if they reflect the fact that cancer cells able to modify their epigenetic programs tend to display higher clinical aggressiveness. Here, ESR1 is linked to breast cancer.